nodes	percent_of_prediction	percent_of_DWPC	metapath
Dipivefrin—ACHE—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.0947	0.0947	CbGpPWpGaD
Dipivefrin—ACHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0545	0.0545	CbGpPWpGaD
Dipivefrin—BCHE—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0486	0.0486	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0185	0.0185	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0183	0.0183	CbGpPWpGaD
Dipivefrin—ACHE—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.018	0.018	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0173	0.0173	CbGpPWpGaD
Dipivefrin—ADRA2B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0158	0.0158	CbGpPWpGaD
Dipivefrin—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0156	0.0156	CbGpPWpGaD
Dipivefrin—ADRA2B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0154	0.0154	CbGpPWpGaD
Dipivefrin—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0152	0.0152	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0151	0.0151	CbGpPWpGaD
Dipivefrin—ADRA2C—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0148	0.0148	CbGpPWpGaD
Dipivefrin—ADRA2C—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0143	0.0143	CbGpPWpGaD
Dipivefrin—ADRA2B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0143	0.0143	CbGpPWpGaD
Dipivefrin—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0141	0.0141	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0141	0.0141	CbGpPWpGaD
Dipivefrin—ADRA2C—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0134	0.0134	CbGpPWpGaD
Dipivefrin—ADRA2B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0133	0.0133	CbGpPWpGaD
Dipivefrin—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0131	0.0131	CbGpPWpGaD
Dipivefrin—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0129	0.0129	CbGpPWpGaD
Dipivefrin—ADRA2B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0129	0.0129	CbGpPWpGaD
Dipivefrin—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0127	0.0127	CbGpPWpGaD
Dipivefrin—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0125	0.0125	CbGpPWpGaD
Dipivefrin—ADRA2C—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0124	0.0124	CbGpPWpGaD
Dipivefrin—ADRA2C—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0121	0.0121	CbGpPWpGaD
Dipivefrin—ADRA2B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.012	0.012	CbGpPWpGaD
Dipivefrin—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.012	0.012	CbGpPWpGaD
Dipivefrin—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0119	0.0119	CbGpPWpGaD
Dipivefrin—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0117	0.0117	CbGpPWpGaD
Dipivefrin—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0116	0.0116	CbGpPWpGaD
Dipivefrin—ADRA2C—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0112	0.0112	CbGpPWpGaD
Dipivefrin—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0109	0.0109	CbGpPWpGaD
Dipivefrin—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0109	0.0109	CbGpPWpGaD
Dipivefrin—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0105	0.0105	CbGpPWpGaD
Dipivefrin—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0101	0.0101	CbGpPWpGaD
Dipivefrin—ADRA2B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.01	0.01	CbGpPWpGaD
Dipivefrin—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00989	0.00989	CbGpPWpGaD
Dipivefrin—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00982	0.00982	CbGpPWpGaD
Dipivefrin—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00979	0.00979	CbGpPWpGaD
Dipivefrin—ADRA2C—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00936	0.00936	CbGpPWpGaD
Dipivefrin—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00912	0.00912	CbGpPWpGaD
Dipivefrin—ADRA2B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00842	0.00842	CbGpPWpGaD
Dipivefrin—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.00841	0.00841	CbGpPWpGaD
Dipivefrin—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00831	0.00831	CbGpPWpGaD
Dipivefrin—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00818	0.00818	CbGpPWpGaD
Dipivefrin—ADRA2C—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00787	0.00787	CbGpPWpGaD
Dipivefrin—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0076	0.0076	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00694	0.00694	CbGpPWpGaD
Dipivefrin—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00688	0.00688	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00673	0.00673	CbGpPWpGaD
Dipivefrin—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00639	0.00639	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00439	0.00439	CbGpPWpGaD
Dipivefrin—ACHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00415	0.00415	CbGpPWpGaD
Dipivefrin—BCHE—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.0037	0.0037	CbGpPWpGaD
Dipivefrin—ADRA2B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00329	0.00329	CbGpPWpGaD
Dipivefrin—ADRA2B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00319	0.00319	CbGpPWpGaD
Dipivefrin—ACHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00318	0.00318	CbGpPWpGaD
Dipivefrin—ADRA2C—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00307	0.00307	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00305	0.00305	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00301	0.00301	CbGpPWpGaD
Dipivefrin—ADRA2C—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00298	0.00298	CbGpPWpGaD
Dipivefrin—ADRA2B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00297	0.00297	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00296	0.00296	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00293	0.00293	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00285	0.00285	CbGpPWpGaD
Dipivefrin—BCHE—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00284	0.00284	CbGpPWpGaD
Dipivefrin—ADRA2C—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00278	0.00278	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00277	0.00277	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00276	0.00276	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00272	0.00272	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00261	0.00261	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00258	0.00258	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00258	0.00258	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00254	0.00254	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00251	0.00251	CbGpPWpGaD
Dipivefrin—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.0025	0.0025	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00249	0.00249	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00244	0.00244	CbGpPWpGaD
Dipivefrin—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00242	0.00242	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00242	0.00242	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00237	0.00237	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00236	0.00236	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00233	0.00233	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00232	0.00232	CbGpPWpGaD
Dipivefrin—ACHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.0023	0.0023	CbGpPWpGaD
Dipivefrin—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00226	0.00226	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00225	0.00225	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00225	0.00225	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00221	0.00221	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00214	0.00214	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00209	0.00209	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00207	0.00207	CbGpPWpGaD
Dipivefrin—BCHE—Metabolism—HDC—Gilles de la Tourette syndrome	0.00205	0.00205	CbGpPWpGaD
Dipivefrin—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00204	0.00204	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00199	0.00199	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00198	0.00198	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00197	0.00197	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00193	0.00193	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00193	0.00193	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00193	0.00193	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00193	0.00193	CbGpPWpGaD
Dipivefrin—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00191	0.00191	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00191	0.00191	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00186	0.00186	CbGpPWpGaD
Dipivefrin—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00183	0.00183	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00181	0.00181	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00181	0.00181	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.0018	0.0018	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00179	0.00179	CbGpPWpGaD
Dipivefrin—ADRA2C—Metabolism—HDC—Gilles de la Tourette syndrome	0.00178	0.00178	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00178	0.00178	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00168	0.00168	CbGpPWpGaD
Dipivefrin—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00166	0.00166	CbGpPWpGaD
Dipivefrin—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00164	0.00164	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00163	0.00163	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00158	0.00158	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00158	0.00158	CbGpPWpGaD
Dipivefrin—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00155	0.00155	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00151	0.00151	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00147	0.00147	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00147	0.00147	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00147	0.00147	CbGpPWpGaD
Dipivefrin—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.00145	0.00145	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00137	0.00137	CbGpPWpGaD
Dipivefrin—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00135	0.00135	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00126	CbGpPWpGaD
Dipivefrin—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00126	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00125	0.00125	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00118	0.00118	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00113	0.00113	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00111	0.00111	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00109	0.00109	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00108	0.00108	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00105	0.00105	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00103	0.00103	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00102	0.00102	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00102	0.00102	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00102	0.00102	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00101	0.00101	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.001	0.001	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000992	0.000992	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000979	0.000979	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000957	0.000957	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000955	0.000955	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000951	0.000951	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000927	0.000927	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000924	0.000924	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000919	0.000919	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000912	0.000912	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000892	0.000892	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000863	0.000863	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000854	0.000854	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000834	0.000834	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000831	0.000831	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000829	0.000829	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00081	0.00081	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000775	0.000775	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000772	0.000772	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000755	0.000755	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000753	0.000753	CbGpPWpGaD
Dipivefrin—ADRA2B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000713	0.000713	CbGpPWpGaD
Dipivefrin—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000704	0.000704	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000701	0.000701	CbGpPWpGaD
Dipivefrin—ADRA2C—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000666	0.000666	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000647	0.000647	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000639	0.000639	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000605	0.000605	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000604	0.000604	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000596	0.000596	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000586	0.000586	CbGpPWpGaD
Dipivefrin—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000582	0.000582	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000579	0.000579	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000564	0.000564	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000547	0.000547	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000546	0.000546	CbGpPWpGaD
Dipivefrin—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000541	0.000541	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000539	0.000539	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000529	0.000529	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00051	0.00051	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000493	0.000493	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000491	0.000491	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000479	0.000479	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000458	0.000458	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000446	0.000446	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000445	0.000445	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000414	0.000414	CbGpPWpGaD
Dipivefrin—ADRA2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000382	0.000382	CbGpPWpGaD
Dipivefrin—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000377	0.000377	CbGpPWpGaD
Dipivefrin—ADRA2C—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000357	0.000357	CbGpPWpGaD
Dipivefrin—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000312	0.000312	CbGpPWpGaD
Dipivefrin—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00029	0.00029	CbGpPWpGaD
